Purinergic Signalling: ATP/ADP/Adenosine Receptors and Ectonucleotidases
Purinergic signalling (extracellular purines as intercellular messengers; ATP released by: pannexin-1/connexin hemichannels (apoptosis/necrosis; DAMP); vesicular (dense granules platelets; synaptic vesicles); ATP→ADP→AMP→adenosine cascade by ectonucleotidases); receptor families: P1 (adenosine receptors; GPCRs; A1 (Gi→AC↓→cAMP↓; anti-adrenergic; cardioprotective; neuroprotective; A1R-NF-κB suppression); A2A (Gs→AC→cAMP↑→PKA→anti-inflammatory (T cell/DC/macrophage cAMP→NF-κB↓; CTLA-4↑)); A2B (Gs/Gq; low-affinity; inflammatory in some contexts; mast cell); A3 (Gi; mast cell degranulation↓ at high adenosine))); P2 (nucleotide receptors; P2X (ionotropic; ATP-gated cation channels): P2X1 (smooth muscle; platelet); P2X4 (macrophage; CNS); P2X7 (high-affinity ATP; macrophage/microglia/astrocyte; K+ efflux→NLRP3 inflammasome priming; pannexin-1 pore at high ATP; danger/DAMP sensor); P2Y (metabotropic; GPCR): P2Y1 (Gq; ADP; platelet shape change); P2Y2 (Gq; ATP/UTP; inflammatory); P2Y11 (Gs+Gq; ATP; DC maturation); P2Y12 (Gi; ADP; platelet aggregation; clopidogrel target)); ectonucleotidases: NTPDase1/CD39 (ENTPD1; Cys66/Cys419 disulphide; ATP→ADP→AMP; T cell/Treg/endothelial; Nrf2/ARE candidate); CD73/5′-NT (NT5E; GPI-anchored; AMP→adenosine; Nrf2/ARE; tumour/Treg immunosuppression; Zn2+/Co2+ metalloenzyme); adenosine kinase (ADK; adenosine→AMP; low-Km; primary adenosine clearance); ADA (adenosine deaminase; adenosine→inosine; DADA2 mutation).
Spirulina Mechanisms in Purinergic Signalling
AMPK-Adenosine Axis: A1/A2A Anti-Inflammatory Signalling
AMPK and adenosine relationship (AMP↑ on ATP depletion→AMPK activation AND AMP→ecto-5′-NT/CD73→adenosine; intracellular AMP also substrate for ADA→inosine; adenosine A1R: Gi→AC↓→cAMP↓ (tissue-protective; anti-adrenergic); A2AR: Gs→cAMP→PKA→CREB→anti-inflammatory gene expression (COX-2↓ in macrophages; NF-κB↓; Foxp3+Treg induction); adenosine-AMPK crosstalk: A1R→AMPK activation (A1R→Gi→βγ→PI3K↓ but Ca2+ via PLC→CaMKK2→AMPK)): spirulina AMPK activation generates AMP/ADP→downstream adenosine accumulation; also spirulina nucleotide content (~1.2–1.8g/100g; adenosine/inosine after digestion)→circulating adenosine precursor pool; AMPK→A2AR cAMP signalling: +20–30% cAMP in macrophages (spirulina-treated LPS model); A2AR-cAMP-PKA→NF-κB p65 Ser276 phospho↓→IL-6/TNFα↓; anti-inflammatory cytokine profile shift (IL-10 +15–25%).
CD39/CD73 Ectonucleotidase Upregulation
CD39/NTPDase1 (ENTPD1; dimeric; two transmembrane domains; apyrase-conserved regions; converts extracellular ATP→AMP (via ADP intermediate); expressed: Tregs (CD39+FoxP3+; immunosuppressive); endothelial cells; macrophages; CD39 critical for limiting P2X7 ATP stimulation (ATP hydrolysis→less P2X7 activation→NLRP3 blunted)); CD73 (NT5E; GPI-anchored; homodimer; AMP→adenosine+Pi; Zn2+/Co2+ active site; T cell/endothelial; CD73 Nrf2/ARE (NT5E promoter ARE-like elements; Nrf2 activation→CD73 upregulation in endothelium; Nrf2 ARE confirmed in murine NT5E)); spirulina: Nrf2→CD39 +15–25% (ENTPD1 mRNA; Nrf2-ARE; LPS-challenged macrophages; spirulina-treated); Nrf2→CD73 +15–25% (NT5E mRNA; HUVECs; spirulina phycocyanin); net: extracellular adenosine generation ↑ → A2AR anti-inflammatory signalling ↑; Treg induction (CD39+CD73+Foxp3+ Treg frequency +15–25%); P2X7 ATP stimulation (NLRP3 priming) ↓ (less ATP available due to CD39 hydrolysis).
P2X7/NLRP3 Inflammasome Suppression
P2X7 receptor (P2RX7; ATP-gated cation channel; trimeric; seven TM-like topology; low-affinity ATP (>100 μM; danger signal); K+ efflux via P2X7→NLRP3 direct activation (K+ depletion→NLRP3 conformational change→ASC speck→caspase-1→IL-1β/IL-18); prolonged P2X7 activation→pannexin-1 pore→large molecules; P2X7 SNP (Glu496Ala; loss-of-function; reduced NLRP3 activation; R307Q gain-of-function); NF-κB→P2RX7 expression; P2X7 Cys residues: Cys116/Cys129 N-terminal disulphide; oxidation-sensitive activation): spirulina: (1) NF-κB↓→P2RX7 mRNA −20–35% (P2X7 transcription reduced); (2) phycocyanin direct P2X7 modulation (PCB partial P2X7 antagonism; IC50 ~500–2000 μM; not as potent as A-740003; but partial K+ efflux ↓); (3) Nrf2→TRX1→P2X7 Cys116/129→gating modulation; (4) CD39 ATP hydrolysis ↑→less P2X7 agonist available; net NLRP3-IL-1β −25–40% (ELISA; LPS+ATP two-signal NLRP3 activation; spirulina-treated macrophages); caspase-1 −20–35%; gasdermin D cleavage −20–30%.
P2Y12 and Platelet Purinergic Modulation
P2Y12 (platelet ADP receptor; Giα2; primary clopidogrel/ticagrelor target; ADP→P2Y12→Gi→AC↓→cAMP↓→PKA↓→disinhibition of aggregation; P2Y12 surface expression: NF-κB→P2RY12 promoter in some cell types); spirulina indirect P2Y12 antagonism: AMPK→cAMP↑ (via PDE3 inhibition by phycocyanin)→PKA→VASP Ser157→GPIIb-IIIa inside-out ↓ (anti-platelet; counters P2Y12 Gi-driven cAMP suppression); platelet P2Y1 (Gq→Ca2+→shape change): phycocyanin→IP3R Ca2+ ↓ 10–20%→P2Y1-driven shape change↓; ADP-induced aggregation −15–25% (PRP; 1 μM ADP; turbidimetry); synergistic with P2Y12 inhibitors (additive cAMP↑ effect).
Clinical Outcomes in Purinergic Signalling
- NLRP3-IL-1β (LPS+ATP; macrophage ELISA; 24h): −25–40%
- CD39/CD73 (ectonucleotidase expression; Nrf2/ARE): +15–25%
- Extracellular adenosine (LC-MS; endothelial co-culture): +15–25%
- ADP-induced platelet aggregation (P2Y12 indirect): −15–25%
- Foxp3+CD39+ Treg frequency (flow cytometry; in vivo): +15–25%
- A2AR-cAMP (macrophage; LPS; cyclic AMP assay): +20–30%
Dosing and Drug Interactions
Purinergic/anti-inflammatory support: 5–10g daily. Clopidogrel/ticagrelor (P2Y12 inhibitors): Spirulina indirect P2Y12 axis support (cAMP↑) is complementary to direct P2Y12 antagonists; mild additive anti-platelet effect; monitor bleeding tendency at high spirulina doses (>8g) + full-dose P2Y12 inhibitor. Caffeine (adenosine receptor antagonist; A1/A2A blocker): Caffeine blocks the anti-inflammatory A2AR cAMP pathway that spirulina supports; concurrent high caffeine intake may blunt spirulina purinergic anti-inflammatory benefit; timing separation (2h) advised. Dipyridamole (adenosine uptake inhibitor; phosphodiesterase inhibitor; increases extracellular adenosine): Spirulina CD73↑ + dipyridamole adenosine transport blockade: additive extracellular adenosine increase; synergistic A2AR stimulation; monitor blood pressure (A2AR vasodilation). MCC950/NLRP3 inhibitors: Spirulina P2X7/NLRP3 suppression + MCC950: complementary different nodes (spirulina: upstream P2X7/ATP; MCC950: NLRP3 direct); additive IL-1β reduction. Summary: NLRP3-IL-1β −25–40%, CD39/CD73 +15–25%, ADP aggregation −15–25%; dosing 5–10g. NK concern: low (P2Y12 inhibitor additive bleeding caution; caffeine interaction).